The possibility of supplying the corona 19 virus vaccine as early as this year is increasing. It is said that vaccines from three major companies, AstraZeneca, Modena, and Pfizer, are at the end of development.

According to major US media on the 3rd (hereafter local time), Pfizer's CEO Albert Buller announced at a meeting of the International Federation of Pharmaceutical Associations that "we will be able to confirm the final results of the corona vaccine clinical trial at the end of October."

Pfizer is developing an mRNA vaccine that targets some of the spike proteins of the coronavirus. The development name is BNT162b1, and it has started phase 3 clinical trials targeting 23,000 people since last July.

In the initial clinical trial (Phase 1/2), positive results were obtained. Neutralizing antibodies were formed in all participants in the clinical trial who administered the vaccine. Their formation of neutralizing antibodies is said to be 1.8 to 2.8 times that of those who have cured Corona 19.

In addition to Pfizer, AstraZeneca in the UK and Modena in the US are confirmed to be in the final stages of developing a COVID-19 vaccine. Among the three companies, AstraZeneca is developing the fastest. AstraZeneca announced on the 31st of last month that "Preliminary results of phase 3 clinical trials will be released in September." AstraZeneca is developing a vaccine in collaboration with Oxford University in the UK. The vaccine under the name "AZD1222" is a recombinant DNA vaccine that targets the spike protein of the Coronavirus 19.

Currently, Russia's Sputnik V is the only product that has been developed as a COVID-19 vaccine in the world. However, criticism is raised that the clinical trial was poorly conducted. It seems that it is not officially recognized by the international community.

In fact, the world's first COVID-19 vaccine title is likely to be taken by one of AstraZeneca, Pfizer, and Modena. It is expected that all three companies will be able to launch within this year.

On the 2nd, it was reported that the Centers for Disease Control and Prevention (CDC) notified each local government in the United States to prepare for the corona 19 vaccine by the end of October. With this, an analysis was raised that the possibility of commercialization of the Corona 19 vaccine increased within the year.

In addition, Anthony Pouch, director of the National Institute of Allergy and Infectious Diseases(NIAID) and director of the FDA, also revealed that if the efficacy of the vaccine candidate under clinical trial is very positive, emergency approval can be obtained before the completion of phase 3 clinical trials. It added strength to the possibility of release within this year.